Sold as Librelease. Every FDA application for this active ingredient: 1 branded and 3 generic.
As of Nov 14, 2026, FDA lists 4 applications for Chlordiazepoxide (sold as Librelease), first approved Sep 12, 1983, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Chlordiazepoxide HCl | Part D | $952K | -7% | 25,010 |
| Sep 12, 1983 | LibreleaseNDA 17813 · New dosage form | Valeant Pharm Intl | 0 | Discontinued |
| — | LibritabsANDA 85481 | Valeant Pharm Intl | 0 | Discontinued |
| — | LibritabsANDA 85482 | Valeant Pharm Intl | 0 | Discontinued |
| — | LibritabsANDA 85488 | Valeant Pharm Intl | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
